While Morgan Stanley maintains an Overweight rating on PDD Holdings, the firm has removed the e-commerce giant from its Top Picks list, citing heightened regulatory scrutiny and a slower-than-expected consumer recovery in China.
As global economic headwinds persist, UK investors are turning to dividend-paying stocks for portfolio resilience. We analyze three FTSE-listed companies with strong income credentials and growth potential for the coming year.
As platforms like Kalshi gain regulatory traction, major online brokerages are making strategic moves into prediction markets. We analyze what this emerging trend could mean for Webull, Robinhood, and Interactive Brokers.
Altria Group reported adjusted earnings growth and robust shareholder returns for 2025, even as it grapples with a rapidly transforming nicotine market dominated by illicit flavored vapes and intense competition in oral tobacco.
DA Davidson joins Morgan Stanley in lowering price targets for language-learning app Duolingo, citing data suggesting daily active user growth may fall short of expectations despite a strong start to the year.
Australia reaffirms its commitment to building resilient critical mineral supply chains and a strategic reserve, undeterred by the U.S. stepping back from plans to guarantee minimum prices for such projects.
ResMed Inc. reports an 11% revenue surge for its second fiscal quarter, driven by robust mask sales and strategic acquisitions, while navigating competitive pressures and capitalizing on emerging healthcare trends.
TAL Education Group's stock soared following a remarkable fiscal Q3 2026 report, showcasing a dramatic turnaround to profitability and robust revenue growth, fueled by strategic investments in educational technology.
Amidst market volatility, a select group of Asian companies with significant insider ownership are drawing investor attention, signaling strong internal belief in their long-term growth trajectories.
Becton Dickinson announces a major spin-off of its Biosciences unit to combine with Waters Corporation, alongside a successful pilot to recycle polystyrene labware, signaling a dual push towards portfolio focus and sustainability.
Amidst a complex backdrop of economic crosscurrents and geopolitical tensions, a select group of small-cap companies across Asia are demonstrating remarkable resilience and growth potential. We analyze three standout names from Singapore and China that are navigating the volatility with strong fundamentals.
With economic crosswinds buffeting regional markets, income-focused investors are increasingly looking to dividend-paying equities in Asia to anchor their portfolios. We examine three prominent names offering compelling yields.
Apple's Q1 earnings smashed expectations, fueled by surging iPhone sales and robust performance in China. While CEO Tim Cook's operational prowess is undeniable, the company's muted AI strategy and reliance on a Google partnership left investors wanting more.
A disappointing full-year EBITDA performance from its crucial Macau operations triggered a sharp sell-off in Las Vegas Sands stock, underscoring the lingering challenges facing the gaming giant in the wake of China's regulatory crackdown.
Dolby Laboratories (NYSE: DLB) kicked off fiscal 2026 with robust first-quarter results, exceeding its own revenue and earnings forecasts. The audio-visual technology leader credits strong deal timing and highlighted significant momentum in automotive, television, and mobile partnerships, including expanded ties with Qualcomm and major social media platforms.
Panama's Supreme Court has nullified long-held port contracts operated by a CK Hutchison subsidiary, declaring them unconstitutional. The landmark ruling throws the future of key container terminals at both ends of the Panama Canal into doubt and reverberates amid broader geopolitical tensions over global trade chokepoints.
The Trump administration has issued a broad license allowing U.S. entities to engage in key oil activities in Venezuela, a major sanctions relief step aimed at jumpstarting the nation's crippled energy industry under its new U.S.-backed leadership.
British pharmaceutical giant AstraZeneca has entered a strategic partnership with China's CSPC Pharmaceutical, committing over $1 billion upfront to co-develop next-generation obesity therapies, signaling intensified competition in the lucrative global weight-loss drug market.
As XPeng shares face sustained pressure, a deep dive into its valuation reveals a stark contradiction: while a fundamental cash flow model suggests significant upside, market-based metrics paint a more cautious picture. We analyze the numbers behind the divergence.
Despite beating earnings estimates, the casino giant's heavy reliance on Macau exposes investor anxieties over long-term regulatory pressures and shifting gambling dynamics in the key Asian market.
